TTM
$25.27B
YoY change
+94.9%
5Y CAGR
+27.2%
Peak year (2025)
$20.64B
Cumulative net income
$138.31B
Net Income history chart for Eli Lilly (LLY) from 1985 to 2025
Latest: $20.64B
Net Income growth chart for Eli Lilly (LLY) from 1985 to 2025
Latest: +94.9%
Net Income history table for Eli Lilly (LLY) from 1985 to 2025
| 2025 | $20.64B | +94.9% | +$10.05B | ||
| 2024 | $10.59B | +102.1% | +$5.35B | ||
| 2023 | $5.24B | -16.1% | −$1.00B | ||
| 2022 | $6.24B | +11.9% | +$663.10M | ||
| 2021 | $5.58B | -9.9% | −$612.00M | ||
| 2020 | $6.19B | -25.5% | −$2.12B | ||
| 2019 | $8.32B | +157.4% | +$5.09B | ||
| 2018 | $3.23B | -1683.5% | +$3.44B | ||
| 2017 | −$204.10M | -107.5% | −$2.94B | ||
| 2016 | $2.74B | +13.7% | +$329.20M | ||
| 2015 | $2.41B | +0.7% | +$17.90M | ||
| 2014 | $2.39B | -49.0% | −$2.29B | ||
| 2013 | $4.68B | +14.6% | +$596.20M | ||
| 2012 | $4.09B | -6.0% | −$259.10M | ||
| 2011 | $4.35B | -14.2% | −$721.80M | ||
| 2010 | $5.07B | +17.1% | +$740.70M | ||
| 2009 | $4.33B | -308.9% | +$6.40B | ||
| 2008 | −$2.07B | -170.2% | −$5.02B | ||
| 2007 | $2.95B | +10.9% | +$290.30M | ||
| 2006 | $2.66B | +34.5% | +$683.10M | ||
| 2005 | $1.98B | +9.4% | +$169.50M | ||
| 2004 | $1.81B | -29.3% | −$750.70M | ||
| 2003 | $2.56B | -5.4% | −$147.10M | ||
| 2002 | $2.71B | -2.6% | −$72.10M | ||
| 2001 | $2.78B | -9.1% | −$277.80M | ||
| 2000 | $3.06B | +12.4% | +$336.80M | ||
| 1999 | $2.72B | +29.7% | +$623.10M | ||
| 1998 | $2.10B | -644.8% | +$2.48B | ||
| 1997 | −$385.10M | -125.3% | −$1.91B | ||
| 1996 | $1.52B | -33.5% | −$767.40M | ||
| 1995 | $2.29B | +78.1% | +$1.00B | ||
| 1994 | $1.29B | +167.8% | +$805.90M | ||
| 1993 | $480.20M | -32.2% | −$228.50M | ||
| 1992 | $708.70M | -46.1% | −$606.00M | ||
| 1991 | $1.31B | +16.6% | +$187.40M | ||
| 1990 | $1.13B | +20.0% | +$187.80M | ||
| 1989 | $939.50M | +23.5% | +$178.50M | ||
| 1988 | $761.00M | +18.2% | +$117.30M | ||
| 1987 | $643.70M | +15.3% | +$85.50M | ||
| 1986 | $558.20M | +7.8% | +$40.60M | ||
| 1985 | $517.60M | — | — |
- 2025$20.64B+94.9%
- 2024$10.59B+102.1%
- 2023$5.24B-16.1%
- 2022$6.24B+11.9%
- 2021$5.58B-9.9%
- 2020$6.19B-25.5%
- 2019$8.32B+157.4%
- 2018$3.23B-1683.5%
- 2017−$204.10M-107.5%
- 2016$2.74B+13.7%
- 2015$2.41B+0.7%
- 2014$2.39B-49.0%
- 2013$4.68B+14.6%
- 2012$4.09B-6.0%
- 2011$4.35B-14.2%
- 2010$5.07B+17.1%
- 2009$4.33B-308.9%
- 2008−$2.07B-170.2%
- 2007$2.95B+10.9%
- 2006$2.66B+34.5%
- 2005$1.98B+9.4%
- 2004$1.81B-29.3%
- 2003$2.56B-5.4%
- 2002$2.71B-2.6%
- 2001$2.78B-9.1%
- 2000$3.06B+12.4%
- 1999$2.72B+29.7%
- 1998$2.10B-644.8%
- 1997−$385.10M-125.3%
- 1996$1.52B-33.5%
- 1995$2.29B+78.1%
- 1994$1.29B+167.8%
- 1993$480.20M-32.2%
- 1992$708.70M-46.1%
- 1991$1.31B+16.6%
- 1990$1.13B+20.0%
- 1989$939.50M+23.5%
- 1988$761.00M+18.2%
- 1987$643.70M+15.3%
- 1986$558.20M+7.8%
- 1985$517.60M—
Net Income values are taken from Eli Lilly's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Net Income at Eli Lilly (LLY)
According to Eli Lilly's latest reported financial statements, the company's current net income (TTM) is $25.27B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Eli Lilly (LLY) reported net income of $20.64B – surged 94.9% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Eli Lilly net income compounded at +27.2% per year, sustaining 2 straight years of year-over-year growth.
The record annual net income stands at $20.64B, reached in 2025; the historical low of −$2.07B was recorded in 2008.
Eli Lilly Net Income by Year
Eli Lilly Net Income 2025: $20.64B
Eli Lilly net income in 2025 was $20.64B, surged 94.9% from 2024. This figure represents the highest annual value in the available history.
Eli Lilly Net Income 2024: $10.59B
2024's net income for Eli Lilly came in at $10.59B, surged 102.1% from 2023.
Eli Lilly Net Income 2023: $5.24B
Eli Lilly posted net income of $5.24B in 2023, declined 16.1% below 2022.
Eli Lilly Net Income 2022: $6.24B
In 2022, Eli Lilly reported net income of $6.24B, grew 11.9% from 2021.
Eli Lilly Net Income 2021: $5.58B
Eli Lilly net income in 2021 was $5.58B.
See more financial history for Eli Lilly (LLY).
Sector peers by Net Income
Healthcare peers of Eli Lilly (LLY), ranked by their latest net income
| $26.80B | |
| $18.25B | |
| $15.97B | |
| $12.06B | |
| $10.26B | |
| $7.71B | |
| $6.74B | |
| $4.23B |
- $26.80B
- $18.25B
- $15.97B
- $12.06B
- $10.26B
- $7.71B
- $4.23B
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation